This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
NVONegative Net Change LLYPositive Net Change GPCRNegative Net Change
biotechs medical pharmaceuticals
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
BMYNo Net Change PFEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
by Zacks Equity Research
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
NVSNegative Net Change BIIBNegative Net Change SUPNPositive Net Change
pharmaceuticals
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
by Kanishka Das
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
JNJNegative Net Change MRKPositive Net Change UTHRNegative Net Change
pharmaceuticals
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
by Zacks Equity Research
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
REGNPositive Net Change SNYPositive Net Change AZNNegative Net Change BAYRYPositive Net Change
pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSNegative Net Change LLYPositive Net Change INCYPositive Net Change EXASNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
REGNPositive Net Change ALNYNegative Net Change NVSNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
by Zacks Equity Research
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
RYPositive Net Change IGCPositive Net Change UVEPositive Net Change ASMNegative Net Change SCRYYPositive Net Change
insurance pharmaceuticals
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
AZNNegative Net Change PFEPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
pharmaceuticals
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
REGNPositive Net Change ALNYNegative Net Change RHHBYNegative Net Change ETNBNegative Net Change
biotechnology earnings medical pharmaceuticals
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
ALNYNegative Net Change NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
by Kinjel Shah
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
AZNNegative Net Change PFEPositive Net Change ABBVNegative Net Change
pharmaceuticals
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
by Zacks Equity Research
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
SNYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change CMMBPositive Net Change
pharmaceuticals
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
by Ekta Bagri
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
BDTXPositive Net Change ORICPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
ALNYNegative Net Change RHHBYNegative Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
ALNYNegative Net Change NVONegative Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
by Kinjel Shah
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
JNJNegative Net Change AMGNNegative Net Change TEVANegative Net Change
pharmaceuticals
Will BMY's Growth Portfolio Drive Third-Quarter Results?
by Ekta Bagri
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
BMYNo Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer's Q3 Non-Oncology Performance: Here's What to Expect
by Kinjel Shah
Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.
BMYNo Net Change PFEPositive Net Change BNTXPositive Net Change
pharmaceuticals
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
by Ahan Chakraborty
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
by Sundeep Ganoria
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs earnings pharmaceuticals
Will Positive Regulatory Updates Further Boost INCY Stock?
by Zacks Equity Research
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
GSKNegative Net Change NVSNegative Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
by Kanishka Das
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
SNYPositive Net Change AZNNegative Net Change MRKPositive Net Change
pharmaceuticals